EGFR and non-small cell lung carcinoma: For example, a study conducted in 2016 by Leduc and al. exploring the incidence rates of EGFR mutations in patients with non-small cell lung cancer of Caribbean origin found a higher rate of a mutation predictive of response to a particular targeted therapy [34].